Greenwich Lifesciences Inc
NASDAQ:GLSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Milux Corporation Bhd
KLSE:MILUX
|
MY |
|
Z
|
Zedge Inc
AMEX:ZDGE
|
US |
|
FriendTimes Inc
HKEX:6820
|
CN |
|
Petpal Pet Nutrition Technology Co Ltd
SZSE:300673
|
CN |
|
CommScope Holding Company Inc
NASDAQ:COMM
|
US |
Greenwich Lifesciences Inc
Total Current Liabilities
Greenwich Lifesciences Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Greenwich Lifesciences Inc
NASDAQ:GLSI
|
Total Current Liabilities
$1.6m
|
CAGR 3-Years
89%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Greenwich Lifesciences Inc
Glance View
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.
See Also
What is Greenwich Lifesciences Inc's Total Current Liabilities?
Total Current Liabilities
1.6m
USD
Based on the financial report for Sep 30, 2025, Greenwich Lifesciences Inc's Total Current Liabilities amounts to 1.6m USD.
What is Greenwich Lifesciences Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
0%
Over the last year, the Total Current Liabilities growth was 93%. The average annual Total Current Liabilities growth rates for Greenwich Lifesciences Inc have been 89% over the past three years .
